ProKidney Corp. (PROK)
XMEX XMEX Primary Summary
ProKidney Corp. (PROK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ProKidney Corp. ever had a stock split?
ProKidney Corp. Profile
| Biotechnology Industry | Healthcare Sector | Bruce Culleton CEO | XMEX Exchange | - ISIN |
| US Country | 231 Employees | - Last Dividend | - Last Split | 12 Jul 2022 IPO Date |
Overview
ProKidney Corp. is a pioneering entity in the biotechnology sector, focusing its efforts on the advancement of cell therapy platforms aimed at the amelioration of chronic kidney diseases. With its inception in 2015, the company has dedicated itself to developing innovative therapeutic solutions from its headquarters in Winston-Salem, North Carolina, USA. The primary mission of ProKidney Corp. is to introduce groundbreaking treatments that offer hope and improved outcomes for patients suffering from various kidney ailments, leveraging the vast potential of cell therapy technologies.
Products and Services
- Renal Autologous Cell Therapy (REACT):
This flagship product embodies the core of ProKidney Corp.'s innovative approach towards tackling chronic kidney diseases. REACT is a cutting-edge therapeutic modality based on the use of autologous homologous cell admixtures. This treatment has successfully completed its Phase I clinical trial, targeting patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). Building upon this initial success, REACT has progressed to Phase III and Phase II clinical trials for addressing moderate to severe diabetic kidney disease, highlighting its potential as a transformative solution for a widespread and impactful health challenge.
